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Acute myelogenous leukemia (AML) can be 
defi  ned as an accumulation of immature mye-
loid cells in the bone marrow and blood result-
ing from dysregulation of normal proliferation, 
diff  erentiation, and apoptosis. AML is the most 
common type of leukemia in adults and occurs 
in approximately one third of newly diagnosed 
patients. Multiple genetic defects have been 
implicated in the pathogenesis of AML (1), 
such as chromosomal deletions or additions, 
and chromosomal translocations resulting in 
production of in-frame fusion proteins. Based 
on current detection techniques, up to 45% of 
AML cases show normal karyotype (2); thus, in 
those cases, point mutations or small rearrange-
ments may aff  ect critical genes. One such gene, 
which is mutated in up to 30% AML cases, is 
the FLT3 receptor tyrosine kinase gene (3). 
The most common (20–25% AML patients) 
form of mutations in FLT3 are small in-frame 
internal tandem duplications (ITDs) in the jux-
tamembrane domain (3–5). In  7% of AML 
cases, point mutations in aspartic acid 835 in 
the kinase domain have been reported as well 
(6, 7). Both types of mutations result in the 
constitutive activation of the FLT3 receptor 
and abnormal activation of the downstream 
pathways: Stat5, Stat3, Akt, and extracellular 
signal–regulated kinase (ERK)1/2 (8–11). Be-
cause FLT3 is normally expressed in early pre-
cursors and plays role in proliferation and 
diff  erentiation of hematopoietic progenitors 
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Mutations constitutively activating FLT3 kinase are detected in  30% of acute myelog-
enous leukemia (AML) patients and affect downstream pathways such as extracellular 
signal–regulated kinase (ERK)1/2. We found that activation of FLT3 in human AML inhibits 
CCAAT/enhancer binding protein 𝗂 (C/EBP𝗂) function by ERK1/2-mediated phosphoryla-
tion, which may explain the differentiation block of leukemic blasts. In MV4;11 cells, 
pharmacological inhibition of either FLT3 or MEK1 leads to granulocytic differentiation. 
Differentiation of MV4;11 cells was also observed when C/EBP𝗂 mutated at serine 21 to 
alanine (S21A) was stably expressed. In contrast, there was no effect when serine 21 was 
mutated to aspartate (S21D), which mimics phosphorylation of C/EBP𝗂. Thus, our results 
suggest that therapies targeting the MEK/ERK cascade or development of protein therapies 
based on transduction of constitutively active C/EBP𝗂 may prove effective in treatment of 
FLT3 mutant leukemias resistant to the FLT3 inhibitor therapies.
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(12, 13), it is not surprising that constitutive activation of 
FLT3 contributes to development of AML. AML patients 
with FLT3 mutations have poor prognosis (14–19). There-
fore, small molecule inhibitors that specifi  cally target FLT3 
activity are undergoing clinical trials (20–23), but so far they 
have produced rather disappointing results. Because FLT3 
regulates an intricate signaling network consisting of multiple 
downstream eff  ectors, identifi  cation of the critical FLT3 tar-
gets involved in mediating the leukemic phenotype will pos-
sibly lead to the identifi  cation of novel alternative therapeutical 
targets for treatment of activated FLT3 leukemias.
Another critical gene involved in the pathogenesis of 
AML is the CCAAT/enhancer binding protein α (C/EBPα). 
C/EBPα is a leucine zipper transcription factor that is impor-
tant for normal myeloid cell diff  erentiation. Within the he-
matopoietic system, expression of C/EBPα is detectable in 
early myeloid precursors and is up-regulated as they commit 
to granulocytic diff  erentiation pathway and mature (24, 25). 
Consistent with this expression pattern, mice lacking C/
EBPα have no mature neutrophils, but rather accumulation 
of myeloblasts in the bone marrow (26). Conversely, overex-
pression of C/EBPα in precursor cell lines triggers neutro-
philic diff  erentiation (24, 27–29). Several studies from our 
group and others’ showed that expression or function of C/
EBPα is inactivated in various types of leukemia (AML and 
CML) by diverse molecular mechanisms (30–40). Impor-
tantly, provision of fully functional C/EBPα into leukemic 
cells could restore their diff  erentiation program (24, 28, 31).
Recently, we have found that C/EBPα can be directly 
phosphorylated by ERK1/2 on S21, which aff  ects the ability 
of C/EBPα to induce diff  erentiation (28). Ectopic expression 
of the phosphomimetic C/EBPα mutant (S21D) inhibited 
granulocytic diff  erentiation (28). In the present work, we 
provide evidence that the activating mutations in FLT3 in 
AML patients and cell lines inactivate C/EBPα function by 
ERK1/2-mediated phosphorylation on S21. Either allevia-
tion of ERK1/2 activity or ectopic expression of a function-
ally active mutant of C/EBPα (S21A) in FLT3 ITD-expressing 
cells rescues myeloid diff  erentiation. Thus, we provide a new 
molecular mechanism by which constitutively active FLT3 
contributes to the pathogenesis of leukemia.
RESULTS
Activation of FLT3 leads to hyperphosphorylation 
of C/EBP𝗂 on serine 21
We hypothesized that the diff  erentiation block in AML 
with     FLT3 activating mutations is mediated by compro-
mised expression and/or function of C/EBPα. Therefore, 
we analyzed C/EBPα mRNA and protein expression in fi  ve 
human FLT3 mutant AML cell lines. Three lines (MOLM-
13, MOLM-14 [reference 41], and MV4;11 [references 42, 
43]) carry ITD mutations (44) and two (MonoMac1 and 
MonoMac6 [reference 45]) have an activating point muta-
tion (V592A) in the juxtamembrane domain (46). All cell 
lines expressed easily detectable C/EBPα mRNA (Fig. 1) 
and protein (Fig. 2, C and F, and not depicted). During 
the treatment with a specifi  c FLT3 inhibitor, MLN518 (47), 
C/EBPα mRNA levels did not change signifi  cantly (Fig. 1). 
Considering that all fi  ve cell lines expressed relatively high 
levels of C/EBPα, which were not up-regulated by MLN518 
treatments (Figs. 1 and 2; not depicted), it appears that the 
suppression of C/EBPα expression by mutated FLT3 is not 
a general mechanism of the diff  erentiation block in human 
AML cell lines.
We have recently reported that the function of C/EBPα 
is inhibited by phosphorylation on S21 by ERK1/2 (28). In-
terestingly, ERK1/2 is one of several downstream signaling 
pathways activated by FLT3 (9, 11). Therefore, we sought 
to determine if C/EBPα protein is phosphorylated upon ac-
tivation of FLT3. As shown in Fig. 2 A, the NH2-terminal 
region of C/EBPα (amino acids 1–119) is specifi  cally phos-
phorylated by ERK1/2 and not by other mitogen-activated 
protein (MAP) kinases. To determine if activation of FLT3 
increases phosphorylation of endogenous C/EBPα, THP-1 
cells, which express C/EBPα and wild-type FLT3 receptor, 
were serum starved and stimulated with FLT3 ligand. West-
ern blot with phospho-specifi  c antibodies (Fig. 2 B) showed 
that stimulation as short as 5 min resulted in a rapid increase 
Figure 1.  Human AML cell lines with activating mutations in FLT3 
express C/EBP𝗂 mRNA. (A) Cell lines (top) were not treated (0) or 
treated with 1 μM MLN518 for 8 or 24 h (indicated above the lanes). 
(top) Hybridization of the Northern blot to a human C/EBPα probe. 
(bottom) A control hybridization to 18S ribosomal RNA. RNA from KG1a 
and U937 cells served as negative and positive controls, respectively. 
(B) The same RNA samples were analyzed in triplicate by TaqMan 
Real-Time PCR and normalized to 18S RNA.JEM VOL. 203, February 20, 2006  373
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Figure 2.  Activation of FLT3 in human AML cells leads to C/EBP𝗂 
protein phosphorylation on S21 by the ERK1/2 pathway. (A) COS7 
cells were untreated or treated with UV-C (60 J/m2; UV) or 100 nM PMA 
and incubated for 60 min. Endogenous c-Jun NH2-terminal protein ki-
nase (JNK), p38, and ERK were immunoprecipitated and used for in vitro 
kinase assays. Control tests showed that ERK phosphorylated Elk1, 
JNK-phosphorylated c-Jun, and p38 MAP kinase phosphorylated ATF2. 
(B) THP-1 cells expressing wild-type FLT3 were serum starved for 6 h (0), 
or starved and stimulated with 100 ng/ml FLT3 ligand (FL) for 5 and 
10 min before harvest. Western blot of whole cell extracts was sequen-
tially stained with pS21-C/EBPα, C/EBPα, pThr202/Tyr204-ERK1/2, and 
β-tubulin antibodies. (C) Human AML cell lines with mutant FLT3 have 
increased phosphorylation of C/EBPα on S21. All cell lines were serum 
starved for 7 h in the absence (−) or presence (+) of 1 μM MLN518. 
Western blot was analyzed as in B. (D) MV4;11 cells were serum starved 
in the absence (−) or presence of the FLT3 inhibitors AG1296 and 
MLN518 at concentrations marked above the lanes, or with vehicle con-
trol (DMSO). Western blot analyses were done as in B. (E) Phosphoryla-
tion status of C/EBPα in MV4;11 and MOLM-13 cells as a dose response 
to MLN518. Cells were serum starved for 7 h in the presence of MLN518 
at concentrations indicated above the lanes. Western blot was stained as 
in B. (F) Time course of FLT3 inhibition and its effect on C/EBPα phos-
phorylation. At each time point, MV4;11, MOLM-13, or MOLM-14 cells 
were serum starved for a total period of 8 h. MLN518 (1 μM) was added 
for the fi  nal hours (indicated above the lanes) of the treatment. For ex-
ample, “1 hr” means that the cells were starved for 7 h in the absence of 
the inhibitor, and for 1 fi  nal hour in its presence. Western blot staining 
was as described previously. (G) Decrease of pS21-C/EBPα by inhibition 
of FLT3 activity in AML patient samples. Leukemic blasts from bone mar-
row (patient no. 592), or peripheral blood (patient no. 667) were cul-
tured in the absence (0), or presence (1) of MLN518 for 6 h. Western 
blot of whole cell extracts was analyzed with antibodies recognizing 
activated FLT3 (P-FLT3), phosphorylated C/EBPα (P-Ser21-C/EBPα), or 
total C/EBPα protein. MV4;11 cells were included for control. Quantifi  ca-
tion of C/EBPα phosphorylation normalized to the total C/EBPα protein 
is shown (bottom).374  INHIBITION OF C/EBPα FUNCTION IN FLT3 MUTANT AML | Radomska et al.
in levels of phosphorylated (activated) ERK1/2 as well as C/
EBPα on S21. We also tested whether constitutive activation 
of mutant FLT3 in AML also results in phosphorylation of 
C/EBPα. All fi  ve cell lines tested (Fig. 2 C and not depicted) 
demonstrated phosphorylation of C/EBPα on S21, which 
correlated with activation of ERK1/2. Treatment of these 
cell lines with MLN518 led to a dramatic reduction in levels 
of pS21C/EBPα, coincident with a decrease in pERK1/2 
levels (Fig. 2 C) and pFLT3 (not depicted). Similarly, treat-
ment of MV4;11 cells with another FLT3 inhibitor, AG1296 
(48), showed a dose-dependent decrease in phosphorylation 
of C/EBPα and ERK1/2 (Fig. 2 D). The absolute levels of 
C/EBPα protein in all fi  ve lines were not signifi  cantly al-
tered by the treatments with any of the inhibitors. Fig. 2 E 
shows that MLN518 reduces pS21-C/EBPα in MV4;11 
and MOLM-13 cells in a dose-dependent manner. When 
normalized for the levels of C/EBPα protein, as little as 0.1 
μM MLN518 led to a threefold decline in pS21-C/EBPα 
levels in both lines, and as great as a 50-fold decrease was 
noted for treatment of MOLM-13 cells with 1 μM inhibi-
tor. A time course experiment using FLT3 ITD cell lines 
was performed to test the kinetics of the MLN518 eff  ect 
on C/EBPα phosphorylation (Fig. 2 F). The inhibition of 
S21 phosphorylation was apparent within the fi  rst 2 h and 
reached maximum between 4 and 6 h. The treatments had 
no eff  ect on the overall levels of C/EBPα protein, but corre-
lated with activation of ERK1/2. Activation of ERK1/2 and 
hyperphosphorylation of C/EBPα were also seen in 293T 
cells transiently cotransfected with FLT3 ITD and wild-type 
C/EBPα expression vectors; these eff  ects were abrogated by 
MLN518 (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20052242/DC1), indicating a causal role of 
activated FLT3.
Next, we sought to determine whether constitutive ac-
tivation of FLT3 aff  ects phosphorylation of C/EBPα in 
AML patients with FLT3 ITD. Primary cells from BM (pa-
tient no. 592) or PBMCs (patient no. 667) were incubated 
in the absence or presence of MLN518, and whole cell ly-
sates were analyzed by Western blot shown in Fig. 2 G. 
Staining with pY591-FLT3 antibody, which detects one of 
the tyrosine residues phosphorylated as a result of activation 
(unpublished data), showed that treatments with MLN518 
led to an  50–60% decrease in FLT3 activation. Inhibition 
of FLT3 in patient samples was also paralleled by a 40–60% 
decrease in pS21-C/EBPα. Control treatment with DMSO 
had no eff  ect on phosphorylation of FLT3 or C/EBPα (un-
published data).
Pharmacological inhibition of FLT3 activation by MLN518 
triggers myeloid differentiation of MV4;11 cells
We showed previously that mutating S21 in C/EBPα to D 
mimics constitutive phosphorylation of S21, inhibits the dif-
ferentiation-promoting activity of C/EBPα, and can inhibit 
retinoic acid-mediated granulocytic diff  erentiation of U937 
cells (28). Therefore, we hypothesized that constitutive acti-
vation of FLT3 may result in diff  erentiation block through 
phosphorylation and thus, inactivation of C/EBPα. Because 
MLN518 decreases the level of FLT3 activation and increases 
the pool of C/EBPα protein not phosphorylated on S21, we 
expected that the treatment with this inhibitor might result 
in the onset of diff  erentiation. As shown in Fig. 3 A, the 3-d 
course of culture of MV4;11 cells with MLN518 in the pres-
ence of serum led to a dramatic decrease in phosphorylation 
of C/EBPα, noted as early as on day 1. In contrast, up to 3 d 
of DMSO treatment had no eff  ect on C/EBPα phosphory-
lation. After 2–3 d of MLN518 treatment, MV4;11 cells ex-
hibited indentation and bending of the nuclei and an increase 
in cytoplasmic/nuclear ratio characteristic of band and meta-
myelocyte stages of granulocytic diff  erentiation (Fig. 3 B). 
Cells treated with 0.05% DMSO for the same period of time 
remained blastic. Morphological changes were accompanied 
by respiratory burst activity determined by Nitro blue tetra-
zolium (NBT) reduction assay (Fig. 3 B), another indicator of 
granulocytic diff  erentiation. Although growth tests indicated 
that the IC50 of MLN518 for this cell line is between 0.3 
and 1 μM (unpublished data), we noted diff  erentiation when 
MV4;11 cells were cultured in 5 or 10 μM MLN518, but not 
in 1 μM (unpublished data). To eliminate the possibility that 
these higher concentrations of MLN518 aff  ects other FLT3-
related receptor kinases, such as c-kit or platelet-  derived 
growth factor receptor (PDGFR), we treated MV4;11 and 
MOLM-13 cells with STI571 (49), and found no eff  ect on 
phosphorylation of C/EBPα (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20052242/DC1).
One of the early events essential for granulocytic diff  er-
entiation is down-regulation of c-myc expression through 
C/EBPα-mediated inhibition of E2F function (50, 51). Very 
rapid down-regulation of c-myc protein was seen in all tested 
FLT3 mutant cell lines in response to MLN518 (Fig. 3 C; not 
depicted). However, because c-myc protein stability is re-
gulated by ERK1/2-mediated phosphorylation (52), we also 
investigated c-myc mRNA levels to eliminate the possibility 
that the decrease in c-myc protein is a result of its dephos-
phorylation and decrease in its stability. Fig. 3 C shows that 
the c-myc down-regulation occurs also at the mRNA level in 
all fi  ve cell lines studied. In all cases, the down-regulation of 
c-myc closely correlated with decrease in pS21-C/EBPα 
(Figs. 2 F and 3 C show the same blot). In support of the diff  er-
entiation onset triggered by MLN518 treatment, we also ob-
served up-regulation of elastase, lysozyme, myeloperoxidase, 
and lactoferrin gene expression in MV4;11 cells (Fig. 3 D). 
In accordance with earlier published data (47), the MLN518-
induced diff  erentiation of MV4;11 cells was accompanied by 
a notable apoptosis (Table S1, available at http://www.jem.
org/cgi/content/full/ jem.20052242/DC1).
Inhibition of MEK1 activity decreases phosphorylation 
of C/EBP𝗂 and induces granulocytic differentiation 
of MV4;11 cells
In addition to the ERK1/2 pathway, activation of FLT3 af-
fects other pathways, such as Stat3/5, or Akt, which are also 
involved in leukemogenesis (8, 9, 11). To determine each JEM VOL. 203, February 20, 2006  375
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pathway’s contribution to the diff  erentiation block in FLT3 
mutant leukemia, we treated MV4;11 cells with a MEK1 in-
hibitor, PD98059, as well as a PI3 kinase inhibitor, LY294002, 
and the JAK-2 protein tyrosine kinase inhibitor, AG490. 
Cells were monitored daily for morphological changes, NBT 
reduction activity, cell growth, and apoptosis. LY294002 and 
AG490 retarded growth and induced apoptosis (Table S1), 
but did not induce diff  erentiation. In contrast, the MEK1 
  inhibitor decreased pS21-C/EBPα levels in as early as 9 h 
(Fig. 4 A) and relieved diff  erentiation block of MV4;11 cells 
(Fig. 4 B). The fi  rst morphological and functional (NBT) 
signs of diff  erentiation were noted 2 d later (Fig. 4 B).   Further 
Figure 3.  Inhibition of FLT3 induces granulocytic differentiation 
of MV4;11 cells. (A) MV4;11 cells were treated with 5 μM MLN518 for 
3 d. Samples were withdrawn daily and phosphorylation of C/EBPα on 
S21 was analyzed by Western blot with phospho-specifi  c (top) and 
C/EBPα (bottom) antibodies. Quantifi  cation of signals with respect to 
total cellular protein levels (as determined by Ponceau S staining) is 
shown (bottom). (B) MV4;11 cells were cultured in the presence of 
5 μM MLN518 or vehicle control (0.05% DMSO). Cell aliquots were 
  examined daily for morphological changes (top) and for NBT reduction 
activity (bottom). Differential counts are summarized in the chart. 
(C) Inhibition of FLT3 leads to down-regulation of c-myc. (top) FLT3 
mutant AML cell lines were serum starved for a total of 8 h in the 
  absence or presence of 1 μM MLN518 for the indicated number of 
hours (at the end of starvation period). Western blot was stained with 
c-myc or β-tubulin antibodies. (bottom) FLT3 mutant lines, MV4;11, 
MOLM-13, MOLM-14, MonoMac1 (MM1), and MonoMac6 (MM6) were 
grown in the absence (0) or presence of 1 μM MLN518 for the indicated 
times (hours). Total RNA was examined by Northern blot with probes 
specifi  c for c-myc and GAPDH (to control for RNA integrity). (D) Up-
regulation of granulocyte-specifi  c gene mRNA in MLN518-treated cells. 
Same RNA samples as in C, were examined by Real Time-PCR with 
primer sets specifi  c for the elastase, lysozyme, myeloperoxidase, and 
lactoferrin genes. Data were normalized for GAPDH RNA and presented 
as fold change.376  INHIBITION OF C/EBPα FUNCTION IN FLT3 MUTANT AML | Radomska et al.
  incubation of cells with MEK1 inhibitor for up to 7 d re-
sulted in even more pronounced granulocytic morphology 
(Fig. 4 B). Thus, we conclude that activation of ERK1/2 
pathway by FLT3 mutations is the main event responsible for 
mediating the diff  erentiation block. Because apoptosis, but 
not diff  erentiation, was noted when cells were treated with 
inhibitors blocking Stat3/5 or Akt pathways, it appears that 
activation of those pathways plays a role in cell survival rather 
than diff  erentiation.
Expression of C/EBP𝗂 mutant lacking Ser21 
phosphorylation relieves the differentiation block 
in FLT3-ITD human AML cells
We have demonstrated that C/EBPα with S21 mutated to 
alanine (S21A), such that it is no longer a substrate for 
ERK1/2 kinases, retains full ability to induce of granulocytic 
diff  erentiation of U937 and K562 cells. In contrast, mutation 
of S21 to aspartate (S21D), which mimics constitutive phos-
phorylation of S21 (S21D) inhibits granulocytic diff  erentia-
tion (28). We predicted that expressing a C/EBPα protein 
lacking the ERK1/2 phosphorylation site (S21A mutant) 
would restore the diff  erentiation of FLT3 mutant AML cells. 
To test this hypothesis, S21A and S21D C/EBPα mutants 
were fused to the estrogen receptor (ER) ligand-binding do-
main and stably introduced into MV4;11 and MOLM-14 
cells. In this system, the expression of C/EBPα-ER proteins 
is constitutive with cytoplasmic localization and their nuclear 
translocation is induced by treatment with β-estradiol (28, 
31, 53). Several independent stable lines of MV4;11 cells were 
established with high expression of C/EBPα-ER (Fig. 5 A; 
not depicted). As assessed by examination of Wright-Giemsa 
stained cells (Fig. 5 B), a 24-h treatment of the MV4;11 stable 
lines expressing S21A-C/EBPα (MV-S21A) with β-estradiol 
resulted in morphological changes typical of granulocytic dif-
ferentiation. These cells also exhibited oxidative burst activity 
(NBT; Fig. 5 B). In contrast, MV4;11 clones expressing the 
S21D mutant of C/EBPα (MV-S21D) did not show any of 
these characteristics and remained immature (Fig. 5 C). Simi-
lar results were obtained in MOLM-14 cells (unpublished 
data). We also tested the eff  ect of induction of the C/EBPα 
mutant proteins on the expression of c-myc. We found that, 
whereas β-estradiol–treated MV-S21A lines down-regulated 
c-myc protein (not depicted) and mRNA (Fig. 5 D), the 
MV-S21D lines maintained c-myc expression (Fig. 5 D). As 
down-regulation of c-myc is a critical event in C/EBPα-
  induced diff  erentiation (50, 51), these results further demon-
strate the importance of nonphosphorylated C/EBPα for 
granulocyte development.
DISCUSSION
FLT3 is overexpressed or coexpressed with FLT3 ligand in 
>90% of AML cases (3, 5), providing another mechanism of 
constitutive receptor activation. Therefore, specifi  c targeting 
of activated FLT3 receptor by small molecule inhibitors is an 
attractive therapeutic approach for AML. Although several 
chemical compounds have been developed to inhibit FLT3 
activity (46–48, 54–56), none of these inhibitors is directed 
solely to the FLT3 receptor; they can aff  ect activities of other 
kinases, such as PKC, TrkA, VEGFR, KIT, or PDGFR, thus 
increasing the possibility of nonspecifi  c toxicity (3, 5). The 
eff  ectiveness of a given inhibitor may also vary depending on 
the actual mutation in the FLT3 receptor, raising a possibility 
of drug resistance. Therefore, elucidating the pathways 
downstream of FLT3 might lead to the development of bet-
ter therapeutic approaches in AML.
The major known eff  ect of all FLT3 inhibitors is the 
induction of apoptosis (47). Ours is the fi  rst report demon-
strating that treatment of FLT3 ITD cells with MLN518, 
in addition to apoptosis, can also trigger diff  erentiation. 
We also showed that inhibition of the ERK1/2 pathway 
in FLT3 mutant AML line could achieve the same eff  ect, 
whereas inhibition of other downstream pathways (Akt, 
Stat3/5) resulted only in apoptosis. Thus, activation of FLT3 
aff   ects signaling pathways controlling both diff  erentiation 
and apoptosis.
Several clinical trials with various FLT3 inhibitors are 
currently in progress (21–23). In one of them, oral admin-
istration of CEP-701 to 14 AML patients expressing FLT3-
  activating mutations demonstrated sustained FLT3 inhibition 
Figure 4.  MV4;11 cells differentiate upon inhibition of the 
ERK1/2 pathway. (A) Western blot showing decreased pS21-C/EBPα 
(top) in response to continuous treatment with 100 μM of the MEK1 
inhibitor PD98059 or vehicle control (DMSO). For DMSO-treated cells, a 
72-h incubation is shown. (bottom) The same blot stained with C/EBPα 
antibody. (B) (top) MV4;11 cell differentiation was monitored by morpho-
logical examination of Wright-Giemsa stained cytospin preparations. Red 
arrows point to cells with granulocytic morphology. (bottom) Respiratory 
burst activity as assessed by the NBT assay.JEM VOL. 203, February 20, 2006  377
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and clinical evidence of biologic activity in only 5 patients 
(22). The same study also showed that two out of eight pa-
tients exhibited >90% inhibition in FLT3 receptor acti-
vation, but remained resistant to the clinical eff  ect of this 
compound. The molecular eff  ects of another FLT3 inhibi-
tor, SU11248, were evaluated on patient samples and showed 
transient or sustained decrease in ERK1/2 activation in 80% 
of patients. Interestingly, activation of the upstream kinase, 
MEK1, was seen in only 39% patients. Thus, components 
of the FLT3–MEK1–ERK1/2 cascade can be dissociated in 
patients (21).
Previously, we have identifi  ed C/EBPα as a transcription 
factor necessary and suffi   cient for neutrophilic diff  erentiation 
(24, 26–29). It was logical to assume that such important 
molecule might be a target in pathogenesis of leukemia. In 
fact, the expression or function of C/EBPα are disturbed in 
various subtypes of leukemia (30–40), providing an explana-
tion for the block in diff  erentiation.
In the course of this work, we show that, in mutant FLT3 
AML, the diff  erentiation-promoting function of C/EBPα is 
inhibited at yet another level: posttranslational modifi  cation 
by phosphorylation. We were able to show, using myeloid 
and 293T cells, that FLT3 activation induces phosphorylation 
of C/EBPα on S21, which inactivates C/EBPα function. 
Consistent with the known role of C/EBPα in promoting 
granulocytic diff  erentiation, inhibition of FLT3 or introduc-
tion into the cells of S21A C/EBPα mutant rescued the dif-
ferentiation block in AML cells. Furthermore, inhibition of 
FLT3 activity decreased the levels of S21 phosphorylation in 
FLT3 mutant cell lines and AML patients. Nonetheless, inhi-
bition of FLT3 was less eff  ective in decreasing the C/EBPα 
phosphorylation in patient samples when compared with cell 
lines. One possible explanation for this diff  erence is that the 
activities of serine/threonine phosphatases, such as protein 
phosphatase 1 (PP1), or MAP kinase phosphatase-1 (MKP-1) 
may be lower in patients (57, 58).
Several groups previously generated 32Dcl3 stable lines 
expressing mutants of FLT3 (59, 60). In those cells, C/EBPα, 
was shown to be down-regulated at the mRNA level (60). 
Also, two out of three FLT3 ITD-positive patients had very 
low levels of C/EBPα mRNA, which increased approxi-
mately twofold following the FLT3 inhibition therapy (60). 
In our own studies with murine 32Dcl3 and 503 (PU.1−/− 
Figure 5.  The dephosphorylated form of C/EBP𝗂 is suffi  cient to 
mediate granulocytic differentiation of MV4;11 cells. (A) MV4;11 
cells were stably transfected with inducible C/EBPα expression vectors. 
Independent clones were analyzed by Western blot. Parental MV4;11 
cells expressing only the endogenous C/EBPα protein are shown (left). 
Clone nos. 7, 25, and 29 express an ectopic C/EBPα-ER fusion protein in 
which S21 of C/EBPα was mutated to alanine (S21A). Clones C, D, and N 
express C/EBPα-ER protein with S21 mutated to aspartate (S21D) to 
mimic phosphorylation. (B) MV4;11 cells with induced expression of 
S21A-C/EBPα protein undergo granulocytic differentiation.   Granulocyte-
specifi  c morphological changes in Wright-Giemsa stained cytospins 
(indicated by red arrows) were seen (top) as well as an increase in NBT 
reduction activity (bottom). (C) Induction of S21D-C/EBPα did not 
  induce granulocytic maturation as shown by morphological examina-
tions (top) or NBT reduction assay (bottom). The inductions shown are 
for 24 h; however, no changes were observed after longer treatments 
with β-estradiol (not depicted). (D) Parental MV4;11 cells and C/EBP-
ER–expressing stable lines (S21A, and S21D) were left untreated (0) or 
treated with 1 μM β-estradiol for 4, 8, and 24 h. RNA was collected and 
analyzed by Northern blot with probes specifi  c for c-myc (top) and 
GAPDH (bottom). For positive controls, K562 and U937 cells were used. 
The U937 stable line with Zn-inducible expression of ectopic C/EBPα 
(reference 24) was included as negative control, as they were shown 
to down-regulate c-myc expression upon induction of C/EBPα expres-
sion (reference 51).378  INHIBITION OF C/EBPα FUNCTION IN FLT3 MUTANT AML | Radomska et al.
line expressing endogenous C/EBPα; unpublished data)  stable 
lines, we found that FLT3 ITD mutation did not lead to a 
strong activation of ERK1/2 and we did not observe an in-
crease in C/EBPα phosphorylation on S21, which is located 
in a protein region highly conserved among mammalian spe-
cies. Furthermore, in a mouse transplantation model, FLT3 
ITD mutations resulted in development of myeloproliferative 
disease rather than AML (61). These fi  ndings suggest that the 
signaling pathways activated by FLT3 are diff  erent in mice 
and humans. In fact, intrinsic diff  erences have been reported 
between mouse and human control of hematopoiesis medi-
ated by C/EBPα (62). We cannot rule out the possibility 
that both C/EBPα-inactivating mechanisms (transcriptional 
repression and functional inhibition) may be operational in 
human FLT3 mutant AML, possibly depending on the dif-
ferentiation stage of the transformed cell.
Overexpression or constitutive activation of the ERK 
pathway has been shown to play an important role in the 
pathogenesis and progression of various cancers (63). Cur-
rently, preclinical trials for pancreas, colon, breast cancers, 
and leukemia are ongoing with compounds specifi  cally inhib-
iting MEK1/2 component of this pathway (64, 65). Abnor-
mal activation of the ERK pathway also occurs in leukemia 
because of the activating mutations in FLT3, Ras, as well as 
genes in other pathways (PI3K, PTEN, Akt) (65). Thus, tar-
geting the Ras–Raf–MEK–ERK pathway in leukemia may 
off  er a potential alternative to standard chemotherapy. It has 
been shown that the primary eff  ect of down-modulation of 
MEK–ERK pathway activation in AML primary blasts by 
a selective inhibitor of MEK1 (PD98059) was a cell cycle 
arrest followed by apoptosis (66). Our results demonstrate 
that PD98059 could decrease pS21-C/EBPα levels in the 
FLT3/ITD AML lines and induce granulocytic diff  erentia-
tion. Our data provide strong indication that inhibitors of 
MEK–ERK cascade could have signifi  cant clinical benefi  t in 
the treatment of FLT3 mutant AML, especially in cases of 
resistance to FLT3 inhibitors. Furthermore, development of 
protein therapies based on transduction of constitutively ac-
tive C/EBPα (such as the S21A mutant) may prove eff  ective 
in treatment of subtypes of leukemia with inadequate expres-
sion/function of C/EBPα.
MATERIALS AND METHODS
Cell lines. MV4;11 (CRL 9591; American Type Culture Collection [refer-
ences 42, 43]), MOLM13, MOLM14 (67), MonoMac1 (68), U937 (CRL 
1593; American Type Culture Collection), and KG1a (CCL 246.1; Ameri-
can Type Culture Collection) were grown in RPMI 1640 with 10% FBS. 
MonoMac6 (45) were cultured in RPMI 1640/10% FBS supplemented with 
MEM Non-Essential Amino Acid Solution and OPI Media Supplement 
(Sigma-Aldrich). THP-1 (TIB 202; American Type Culture Collection) 
were grown in RPMI 1640/10% FBS with 0.05 mM β-mercaptoethanol. 
For MV4;11 stable lines, phenol red-free RPMI 1640/10% charcoal dextran 
stripped FBS and 0.25 μg/ml puromycin were used.
Patient samples. Patient samples were obtained from bone marrow (pa-
tient no. 592) or peripheral blood (patient no. 667) at the Laboratory of 
Leukemia Diagnostic, Grosshadern. Samples were collected at time of diag-
nosis before initiation of treatment. The percentage of blasts in the samples 
was 70% (patient no. 592; male, 71 yr, FAB M2, 46, XY [25], MLL-PTD−, 
FLT3-LM+, FLT3-TKD−, KIT−, NRAS−) and 95% (patient no. 667; fe-
male, 74 yr, FAB M1, 47, XX, +8 [20], MLL-PTD+, FLT3-LM+, FLT3-
TKD−, KIT−, NRAS−). Blast cells were collected after patient consent, 
purifi   ed by Ficoll-Hypaque density centrifugation, and frozen in 40% 
IMDM/50% FCS/10% DMSO. Cells were thawed in IMDM/20% FCS, 
400 IE/ml Heparin, 100 U/ml DNase, washed once in IMDM (without se-
rum), and incubated at 37°C for 6 h in IMDM with or without MLN518, 
or with DMSO (vehicle control).
Reagents. FLT3 inhibitor MLN518 (CT53518) (47) and FLT3/PDGFR 
inhibitor AG1296 were reconstituted in DMSO at 10 mM. PD98059 
(MEK1 inhibitor), LY294002 (PI3 kinase inhibitor), and tyrphostin AG490 
(JAK2 inhibitor) were dissolved in DMSO to 50 mM. The fi  nal concentra-
tions were 25 μM or 50 μM for LY294002, and 50 μM or 100 μM for 
AG490. Recombinant human FLT3 ligand was reconstituted at 10 μg/ml. 
All reagents, except MLN518 (kept at 4°C) were stored at −20°C.
In vitro kinase assays. Protein kinase assays were performed as described 
previously (69). The details are provided in the supplemental Materials 
and methods section (available at http://www.jem.org/cgi/content/full/
jem.20052242/DC1).
Western blot. 5 × 106 cells were spun (1 K, 5 min), washed in PBS, lysed 
in 400 μl of 1× Laemmli sample buff  er (70), and boiled at 100°C for 10 min. 
30–40 μl were loaded on 7.5% SDS-PAGE gel. After blocking in 5% milk/
TBST (TBST: 25 mM Tris-HCl, pH 7.4, 137 mM NaCl, 2.7 mM KCl, 
0.1% Tween 20), membranes were stained with primary antibodies in 5% 
BSA/TBST/0.1% sodium azide overnight at 4°C and with horseradish per-
oxidase (HRP)–conjugated secondary antibodies at room temperature for 
1 h. Signals were detected by enhanced chemiluminescence and quantifi  ed 
by ImageQuant software (Molecular Dynamics). The primary antibodies 
were rabbit pS21-C/EBPα (1:1,000; Cell Signaling), goat C/EBPα (1:1,000; 
Santa Cruz Biotechnology, Inc.), pY591-FLT3 (1:1,000 54H1; Cell Signal-
ing), rabbit p(T202/Y204)-ERK1/2 (1:1,000; Cell Signaling), and β-  tubulin 
(1:1,000 clone 2–28-33; Sigma-Aldrich). All secondary antibodies were 
HRP-conjugated (Santa Cruz Biotechnology, Inc.) and diluted 1:5,000 for 
rabbit-HRP, 1:3,000 for mouse-HRP, and 1:2,000 for goat-HRP.
Plasmids. pBabe-(S21A)C/EBPαER and pBabe-(S21D)C/EBPαER plas-
mids were described previously (28). They contained coding regions of mu-
rine C/EBPα mutated in S21 and fused to the human ER ligand-binding 
domain. Puromycin gene was included for stable line selection.
Transfections. Stable lines were made by Nucleofection (Amaxa). Cells 
were grown in phenol red-free RPMI 1640/10% charcoal-stripped FBS for 
at least 48 h before transfection. 107 cells were mixed with 100 μl of Nucleo-
fector Solution T and 5 μg of ScaI linearized plasmid. Pulses were delivered 
with Nucleofector device and program T-05. Cells were resuspended in 
10 ml of phenol red-free RPMI 1640/20% charcoal-stripped FBS supple-
mented with 10% of MV4;11 cells-conditioned medium and plated on 96-well 
plates. Selection with 0.25 μg/ml puromycin was performed 72 h later.
RNA isolation and analysis. Total RNA was isolated with TriReagent. 
For Northern blots, 20 μg of RNA was separated on agarose gels and trans-
ferred to Biotrans Plus membranes. The blots were hybridized to the 700-bp 
EcoRI–HindIII fragment of the human C/EBPα 3′ UTR (24) and a 305-bp 
XbaI–EcoRI cDNA fragment of human c-myc (50). For loading control, 
the blots were stripped and rehybridized to GAPDH or 18S ribosomal RNA 
probes. Quantitation was performed with Image Quant. Details on SYBR 
green and TaqMan Real-Time PCR assays are provided in supplemental 
Materials and methods.
Morphological examination. Approximately 104 cells were spun at 500 
revolutions/min for 5 min onto glass slides and Wright-Giemsa stained with JEM VOL. 203, February 20, 2006  379
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Diff  Quick solutions (Dade Behring). Diff  erential counts were performed on 
at least 10 fi  elds from each slide.
Nitroblue tetrazolium reduction assay. 5 × 105 cells were incubated in 
0.5 ml solution containing PBS, NBT (1 tablet in 10 ml PBS; Sigma-
  Aldrich), and 0.33 μM PMA for 20–30 min at 37°C. Cytospin slides were 
prepared and counterstained with 0.5% safranin in 20% ethanol.
Online supplemental material. In Fig. S1, FLT3 ITD mutant induces 
activation of ERK1/2 pathway and phosphorylation of C/EBPα on S21 
in transiently transfected 293T cells. Fig. S2 shows that a c-kit and PDGFR 
inhibitor, STI571, do not aff  ect levels of pS21-C/EBPα in FLT3 ITD cell 
lines. Table S1 depicts FLT3, PI3K, and Jak2 inhibitors that induce apopto-
sis of MV4;11 cells. Supplemental Materials and methods contains descrip-
tion of procedures for an in vitro kinase assay and real-time PCR. Online 
supplemental material is available at http://www.jem.org/cgi/content/full/
jem.20052242/DC1.
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